deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT03517176

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer

Sponsor: Lisata Therapeutics, Inc.

Conditions Pancreatic Cancer Pancreatic Ductal Adenocarcinoma
Interventions CEND-1 Gemcitabine Nab-paclitaxel
Updated 15 times since 2018 Last updated: Aug 26, 2024 Started: Jul 31, 2018 Primary completion: Jun 19, 2020 Completion: Jun 19, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma and is currently completed. Lisata Therapeutics, Inc. leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Oct 2019 · 8 months · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~Nov 2020 · 10 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Nov 2022 · 22 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Nov 2022 [monthly]

    Completed PHASE1

  5. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 10 earlier versions

  1. Jan 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Oct 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  3. Feb 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  4. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1

  5. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  6. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  7. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  8. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  9. Aug 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE1

  10. Jun 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Lisata Therapeutics, Inc.
Data source: Lisata Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations